Cannabis / Cbd
Rescheduling Cannabis: Economic Opportunities for Biotech and Rare‑Disease Research
Picture a scientist who’s spent years waiting for a key to a locked lab door. In 2024, Congress finally turned that key, moving cannabis from Schedule I to Schedule III and opening a hallway of federal dollars, faster trials, and a more attractive investment landscape. The ripple effects are